Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) - HC Wainwright decreased their Q1 2025 earnings per share (EPS) estimates for shares of Milestone Pharmaceuticals in a report released on Monday, March 17th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of ($0.18) per share for the quarter, down from their prior forecast of ($0.17). HC Wainwright has a "Buy" rating and a $25.00 price target on the stock. The consensus estimate for Milestone Pharmaceuticals' current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for Milestone Pharmaceuticals' Q2 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($1.02) EPS, FY2026 earnings at ($0.89) EPS and FY2027 earnings at ($0.02) EPS.
Milestone Pharmaceuticals Trading Up 7.9 %
Shares of MIST traded up $0.15 during trading hours on Thursday, reaching $2.05. 3,495,309 shares of the company traded hands, compared to its average volume of 464,852. The stock's fifty day moving average price is $2.01 and its 200 day moving average price is $1.83. The company has a current ratio of 15.40, a quick ratio of 15.40 and a debt-to-equity ratio of 2.18. The firm has a market cap of $109.38 million, a price-to-earnings ratio of -2.53 and a beta of 1.83. Milestone Pharmaceuticals has a 12-month low of $1.12 and a 12-month high of $2.75.
Institutional Investors Weigh In On Milestone Pharmaceuticals
Several large investors have recently added to or reduced their stakes in MIST. Toronto Dominion Bank bought a new stake in shares of Milestone Pharmaceuticals during the fourth quarter valued at approximately $1,770,000. Boxer Capital Management LLC purchased a new position in Milestone Pharmaceuticals during the 4th quarter worth $729,000. Virtu Financial LLC bought a new stake in Milestone Pharmaceuticals during the 4th quarter valued at $170,000. XTX Topco Ltd purchased a new stake in shares of Milestone Pharmaceuticals in the 4th quarter worth $80,000. Finally, Cubist Systematic Strategies LLC bought a new position in shares of Milestone Pharmaceuticals during the 4th quarter worth $73,000. 86.18% of the stock is owned by hedge funds and other institutional investors.
About Milestone Pharmaceuticals
(
Get Free Report)
Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.
Featured Articles
Before you consider Milestone Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Milestone Pharmaceuticals wasn't on the list.
While Milestone Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
